WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524111

CAS#: 1008529-42-7

Description: ABT-116 is an antagonist of transient receptor potential vanilloid type 1.

Price and Availability




ABT-116, purity > 98%, is not in stock, may be available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 524111
Name: ABT-116
CAS#: 1008529-42-7
Chemical Formula: C23H27F3N4O
Exact Mass: 432.2137
Molecular Weight: 432.48
Elemental Analysis: C, 63.87; H, 6.29; F, 13.18; N, 12.95; O, 3.70

Synonym: ABT-116; ABT 116; ABT116;

IUPAC/Chemical Name: 1-(2-(3,3-dimethylbutyl)-4-(trifluoromethyl)benzyl)-3-(1-methyl-1H-indazol-4-yl)urea


InChi Code: InChI=1S/C23H27F3N4O/c1-22(2,3)11-10-15-12-17(23(24,25)26)9-8-16(15)13-27-21(31)29-19-6-5-7-20-18(19)14-28-30(20)4/h5-9,12,14H,10-11,13H2,1-4H3,(H2,27,29,31)

SMILES Code: CC(C)(CCc1c(CNC(Nc2c3cnn(C)c3ccc2)=O)ccc(C(F)(F)F)c1)C

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Niyom S, Mama KR, Gustafson DL, Rezende ML. Single- and multiple dose
pharmacokinetics and multiple dose pharmacodynamics of oral ABT-116 (a TRPV1
antagonist) in dogs. J Vet Pharmacol Ther. 2015 Aug;38(4):336-43. doi:
10.1111/jvp.12180. Epub 2014 Nov 5. PubMed PMID: 25376244.

2: Malek S, Sample SJ, Schwartz Z, Nemke B, Jacobson PB, Cozzi EM, Schaefer SL,
Bleedorn JA, Holzman G, Muir P. Effect of analgesic therapy on clinical outcome
measures in a randomized controlled trial using client-owned dogs with hip
osteoarthritis. BMC Vet Res. 2012 Oct 4;8:185. doi: 10.1186/1746-6148-8-185.
PubMed PMID: 23035739; PubMed Central PMCID: PMC3527270.

3: Niyom S, Mama KR, De Rezende ML. Comparison of the analgesic efficacy of oral
ABT-116 administration with that of transmucosal buprenorphine administration in
dogs. Am J Vet Res. 2012 Apr;73(4):476-81. doi: 10.2460/ajvr.73.4.476. PubMed
PMID: 22452493.

4: Cathcart CJ, Johnston SA, Reynolds LR, Al-Nadaf S, Budsberg SC. Efficacy of
ABT-116, an antagonist of transient receptor potential vanilloid type 1, in
providing analgesia for dogs with chemically induced synovitis. Am J Vet Res.
2012 Jan;73(1):19-26. doi: 10.2460/ajvr.73.1.19. PubMed PMID: 22204284.

5: Brown BS, Keddy R, Perner RJ, DiDomenico S, Koenig JR, Jinkerson TK, Hannick
SM, McDonald HA, Bianchi BR, Honore P, Puttfarcken PS, Moreland RB, Marsh KC,
Faltynek CR, Lee CH. Discovery of TRPV1 antagonist ABT-116. Bioorg Med Chem Lett.
2010 Jun 1;20(11):3291-4. doi: 10.1016/j.bmcl.2010.04.047. Epub 2010 Apr 14.
PubMed PMID: 20457518.